meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population 5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative 1
mNSCLC - L1 - PDL1 positive 14
mNSCLC - L1 - TMB>10Mb 1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population 3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT) 6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population 4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)

immune chekpoint inhibitors
anti-PD-(L)1
cemiplimab
durvalumab based treatment
durvalumab alone
sintilimab based treatment
sintillimab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC

versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -